SecBot SecBot
SECBOTREPLAY Home › Report › PSNL

PSNL · Q3 revenue +77% YoY

Personalis, Inc. · 8-K filed Nov 4, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Nov 4, 2026 at 16:05 ET

Personalis reported Q3 2026 total revenue of $25.6M, up 77% YoY from $14.5M, driven by clinical test revenue surging to $4.4M from $0.4M and population sequencing revenue of $4.0M vs $0.2M. Net loss widened to $33.8M from $21.7M, with SG&A expense doubling to $26.0M largely due to merger-related costs. The company withdrew guidance and will not hold an earnings call due to the pending Tempus acquisition announced July 20, 2026.

  • Total revenue $25.6M vs $14.5M YoY (+77%)
  • Clinical test revenue $4.4M vs $0.4M YoY, volume 13,157 tests vs 4,388
  • Pharma testing services revenue $17.1M vs $13.1M YoY
  • Population sequencing (VA MVP) revenue $4.0M vs $0.2M YoY

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access